The Experts below are selected from a list of 7542 Experts worldwide ranked by ideXlab platform

Russell J Mumper - One of the best experts on this subject based on the ideXlab platform.

  • Blood compatibility of cetyl alcohol polysorbate based nanoparticles
    Pharmaceutical Research, 2005
    Co-Authors: Joanna M Koziara, Jennifer J Oh, W S Akers, S P Ferraris, Russell J Mumper
    Abstract:

    Pegylated and nonpegylated cetyl alcohol/polysorbate nanoparticles (E78 NPs) are being tested as drug carriers for specific tumor and brain targeting. Because these nanoparticle formulations are designed for systemic administration, it is important to test the compatibility of these lipid-based NPs with Blood and Blood cells. The hemocompatibility of E78 NPs was evaluated with a particular focus on hemolytic activity, platelet function, and Blood coagulation. Human red Blood cell lysis was determined by measuring hemoglobin release. Activation and aggregation of human platelets were determined using flow cytometry and aggregometry, respectively. Finally, the whole Blood Clotting Time was measured using human Blood. E78 NPs did not cause in vitro red Blood cell lysis at concentrations up to 1 mg/mL. In addition, under conditions tested, E78 and polyethylene glycol (PEG)-coated E78 NPs (PEG-E78 NPs) did not activate platelets. In fact, both NP formulations very rapidly inhibited agonist-induced platelet activation and aggregation in a dose-dependent manner. Additionally, E78 NPs significantly prolonged in vitro whole Blood Clotting Time at a concentration of 500 μg/mL or greater. It was concluded that PEG-coated and nonpegylated E78 NPs have potential Blood compatibility at clinically relevant doses. Based on the calculated nanoparticle-to-platelet ratio, the concentration at which E78 NPs could potentially affect platelet function in vivo was approximately 1 mg/mL.

  • Blood compatibility of cetyl alcohol polysorbate based nanoparticles
    Pharmaceutical Research, 2005
    Co-Authors: Joanna M Koziara, W S Akers, S P Ferraris, Russell J Mumper
    Abstract:

    Pegylated and nonpegylated cetyl alcohol/polysorbate nanoparticles (E78 NPs) are being tested as drug carriers for specific tumor and brain targeting. Because these nanoparticle formulations are designed for systemic administration, it is important to test the compatibility of these lipid-based NPs with Blood and Blood cells. The hemocompatibility of E78 NPs was evaluated with a particular focus on hemolytic activity, platelet function, and Blood coagulation. Human red Blood cell lysis was determined by measuring hemoglobin release. Activation and aggregation of human platelets were determined using flow cytometry and aggregometry, respectively. Finally, the whole Blood Clotting Time was measured using human Blood. E78 NPs did not cause in vitro red Blood cell lysis at concentrations up to 1 mg/mL. In addition, under conditions tested, E78 and polyethylene glycol (PEG)-coated E78 NPs (PEG-E78 NPs) did not activate platelets. In fact, both NP formulations very rapidly inhibited agonist-induced platelet activation and aggregation in a dose-dependent manner. Additionally, E78 NPs significantly prolonged in vitro whole Blood Clotting Time at a concentration of 500 μg/mL or greater. It was concluded that PEG-coated and nonpegylated E78 NPs have potential Blood compatibility at clinically relevant doses. Based on the calculated nanoparticle-to-platelet ratio, the concentration at which E78 NPs could potentially affect platelet function in vivo was approximately 1 mg/mL.

Joanna M Koziara - One of the best experts on this subject based on the ideXlab platform.

  • Blood compatibility of cetyl alcohol polysorbate based nanoparticles
    Pharmaceutical Research, 2005
    Co-Authors: Joanna M Koziara, Jennifer J Oh, W S Akers, S P Ferraris, Russell J Mumper
    Abstract:

    Pegylated and nonpegylated cetyl alcohol/polysorbate nanoparticles (E78 NPs) are being tested as drug carriers for specific tumor and brain targeting. Because these nanoparticle formulations are designed for systemic administration, it is important to test the compatibility of these lipid-based NPs with Blood and Blood cells. The hemocompatibility of E78 NPs was evaluated with a particular focus on hemolytic activity, platelet function, and Blood coagulation. Human red Blood cell lysis was determined by measuring hemoglobin release. Activation and aggregation of human platelets were determined using flow cytometry and aggregometry, respectively. Finally, the whole Blood Clotting Time was measured using human Blood. E78 NPs did not cause in vitro red Blood cell lysis at concentrations up to 1 mg/mL. In addition, under conditions tested, E78 and polyethylene glycol (PEG)-coated E78 NPs (PEG-E78 NPs) did not activate platelets. In fact, both NP formulations very rapidly inhibited agonist-induced platelet activation and aggregation in a dose-dependent manner. Additionally, E78 NPs significantly prolonged in vitro whole Blood Clotting Time at a concentration of 500 μg/mL or greater. It was concluded that PEG-coated and nonpegylated E78 NPs have potential Blood compatibility at clinically relevant doses. Based on the calculated nanoparticle-to-platelet ratio, the concentration at which E78 NPs could potentially affect platelet function in vivo was approximately 1 mg/mL.

  • Blood compatibility of cetyl alcohol polysorbate based nanoparticles
    Pharmaceutical Research, 2005
    Co-Authors: Joanna M Koziara, W S Akers, S P Ferraris, Russell J Mumper
    Abstract:

    Pegylated and nonpegylated cetyl alcohol/polysorbate nanoparticles (E78 NPs) are being tested as drug carriers for specific tumor and brain targeting. Because these nanoparticle formulations are designed for systemic administration, it is important to test the compatibility of these lipid-based NPs with Blood and Blood cells. The hemocompatibility of E78 NPs was evaluated with a particular focus on hemolytic activity, platelet function, and Blood coagulation. Human red Blood cell lysis was determined by measuring hemoglobin release. Activation and aggregation of human platelets were determined using flow cytometry and aggregometry, respectively. Finally, the whole Blood Clotting Time was measured using human Blood. E78 NPs did not cause in vitro red Blood cell lysis at concentrations up to 1 mg/mL. In addition, under conditions tested, E78 and polyethylene glycol (PEG)-coated E78 NPs (PEG-E78 NPs) did not activate platelets. In fact, both NP formulations very rapidly inhibited agonist-induced platelet activation and aggregation in a dose-dependent manner. Additionally, E78 NPs significantly prolonged in vitro whole Blood Clotting Time at a concentration of 500 μg/mL or greater. It was concluded that PEG-coated and nonpegylated E78 NPs have potential Blood compatibility at clinically relevant doses. Based on the calculated nanoparticle-to-platelet ratio, the concentration at which E78 NPs could potentially affect platelet function in vivo was approximately 1 mg/mL.

S P Ferraris - One of the best experts on this subject based on the ideXlab platform.

  • Blood compatibility of cetyl alcohol polysorbate based nanoparticles
    Pharmaceutical Research, 2005
    Co-Authors: Joanna M Koziara, Jennifer J Oh, W S Akers, S P Ferraris, Russell J Mumper
    Abstract:

    Pegylated and nonpegylated cetyl alcohol/polysorbate nanoparticles (E78 NPs) are being tested as drug carriers for specific tumor and brain targeting. Because these nanoparticle formulations are designed for systemic administration, it is important to test the compatibility of these lipid-based NPs with Blood and Blood cells. The hemocompatibility of E78 NPs was evaluated with a particular focus on hemolytic activity, platelet function, and Blood coagulation. Human red Blood cell lysis was determined by measuring hemoglobin release. Activation and aggregation of human platelets were determined using flow cytometry and aggregometry, respectively. Finally, the whole Blood Clotting Time was measured using human Blood. E78 NPs did not cause in vitro red Blood cell lysis at concentrations up to 1 mg/mL. In addition, under conditions tested, E78 and polyethylene glycol (PEG)-coated E78 NPs (PEG-E78 NPs) did not activate platelets. In fact, both NP formulations very rapidly inhibited agonist-induced platelet activation and aggregation in a dose-dependent manner. Additionally, E78 NPs significantly prolonged in vitro whole Blood Clotting Time at a concentration of 500 μg/mL or greater. It was concluded that PEG-coated and nonpegylated E78 NPs have potential Blood compatibility at clinically relevant doses. Based on the calculated nanoparticle-to-platelet ratio, the concentration at which E78 NPs could potentially affect platelet function in vivo was approximately 1 mg/mL.

  • Blood compatibility of cetyl alcohol polysorbate based nanoparticles
    Pharmaceutical Research, 2005
    Co-Authors: Joanna M Koziara, W S Akers, S P Ferraris, Russell J Mumper
    Abstract:

    Pegylated and nonpegylated cetyl alcohol/polysorbate nanoparticles (E78 NPs) are being tested as drug carriers for specific tumor and brain targeting. Because these nanoparticle formulations are designed for systemic administration, it is important to test the compatibility of these lipid-based NPs with Blood and Blood cells. The hemocompatibility of E78 NPs was evaluated with a particular focus on hemolytic activity, platelet function, and Blood coagulation. Human red Blood cell lysis was determined by measuring hemoglobin release. Activation and aggregation of human platelets were determined using flow cytometry and aggregometry, respectively. Finally, the whole Blood Clotting Time was measured using human Blood. E78 NPs did not cause in vitro red Blood cell lysis at concentrations up to 1 mg/mL. In addition, under conditions tested, E78 and polyethylene glycol (PEG)-coated E78 NPs (PEG-E78 NPs) did not activate platelets. In fact, both NP formulations very rapidly inhibited agonist-induced platelet activation and aggregation in a dose-dependent manner. Additionally, E78 NPs significantly prolonged in vitro whole Blood Clotting Time at a concentration of 500 μg/mL or greater. It was concluded that PEG-coated and nonpegylated E78 NPs have potential Blood compatibility at clinically relevant doses. Based on the calculated nanoparticle-to-platelet ratio, the concentration at which E78 NPs could potentially affect platelet function in vivo was approximately 1 mg/mL.

W S Akers - One of the best experts on this subject based on the ideXlab platform.

  • Blood compatibility of cetyl alcohol polysorbate based nanoparticles
    Pharmaceutical Research, 2005
    Co-Authors: Joanna M Koziara, Jennifer J Oh, W S Akers, S P Ferraris, Russell J Mumper
    Abstract:

    Pegylated and nonpegylated cetyl alcohol/polysorbate nanoparticles (E78 NPs) are being tested as drug carriers for specific tumor and brain targeting. Because these nanoparticle formulations are designed for systemic administration, it is important to test the compatibility of these lipid-based NPs with Blood and Blood cells. The hemocompatibility of E78 NPs was evaluated with a particular focus on hemolytic activity, platelet function, and Blood coagulation. Human red Blood cell lysis was determined by measuring hemoglobin release. Activation and aggregation of human platelets were determined using flow cytometry and aggregometry, respectively. Finally, the whole Blood Clotting Time was measured using human Blood. E78 NPs did not cause in vitro red Blood cell lysis at concentrations up to 1 mg/mL. In addition, under conditions tested, E78 and polyethylene glycol (PEG)-coated E78 NPs (PEG-E78 NPs) did not activate platelets. In fact, both NP formulations very rapidly inhibited agonist-induced platelet activation and aggregation in a dose-dependent manner. Additionally, E78 NPs significantly prolonged in vitro whole Blood Clotting Time at a concentration of 500 μg/mL or greater. It was concluded that PEG-coated and nonpegylated E78 NPs have potential Blood compatibility at clinically relevant doses. Based on the calculated nanoparticle-to-platelet ratio, the concentration at which E78 NPs could potentially affect platelet function in vivo was approximately 1 mg/mL.

  • Blood compatibility of cetyl alcohol polysorbate based nanoparticles
    Pharmaceutical Research, 2005
    Co-Authors: Joanna M Koziara, W S Akers, S P Ferraris, Russell J Mumper
    Abstract:

    Pegylated and nonpegylated cetyl alcohol/polysorbate nanoparticles (E78 NPs) are being tested as drug carriers for specific tumor and brain targeting. Because these nanoparticle formulations are designed for systemic administration, it is important to test the compatibility of these lipid-based NPs with Blood and Blood cells. The hemocompatibility of E78 NPs was evaluated with a particular focus on hemolytic activity, platelet function, and Blood coagulation. Human red Blood cell lysis was determined by measuring hemoglobin release. Activation and aggregation of human platelets were determined using flow cytometry and aggregometry, respectively. Finally, the whole Blood Clotting Time was measured using human Blood. E78 NPs did not cause in vitro red Blood cell lysis at concentrations up to 1 mg/mL. In addition, under conditions tested, E78 and polyethylene glycol (PEG)-coated E78 NPs (PEG-E78 NPs) did not activate platelets. In fact, both NP formulations very rapidly inhibited agonist-induced platelet activation and aggregation in a dose-dependent manner. Additionally, E78 NPs significantly prolonged in vitro whole Blood Clotting Time at a concentration of 500 μg/mL or greater. It was concluded that PEG-coated and nonpegylated E78 NPs have potential Blood compatibility at clinically relevant doses. Based on the calculated nanoparticle-to-platelet ratio, the concentration at which E78 NPs could potentially affect platelet function in vivo was approximately 1 mg/mL.

Hui-ming Tsou - One of the best experts on this subject based on the ideXlab platform.

  • electrochemical polymerization of pedot graphene oxide heparin composite coating for anti fouling and anti Clotting of cardiovascular stents
    Polymers, 2019
    Co-Authors: Ming-chien Yang, Yu-sheng Hsiao, Che-chun Liu, Xin-yao Peng, Ming-chi Yung, Ting-yu Liu, Li Ying Huang, Hui-ming Tsou, Yu-wei Cheng, Chuan-chih Hsu
    Abstract:

    In this study, a novel hemocompatible coating on stainless steel substrates was prepared by electrochemically copolymerizing 3,4-ethylenedioxythiophene (EDOT) with graphene oxide (GO), polystyrene sulfonate (PSS), or heparin (HEP) on SUS316L stainless steel, producing an anti-fouling (anti-protein adsorption and anti-platelet adhesion) surface to avoid the restenosis of Blood vessels. The negative charges of GO, PSS, and HEP repel negatively charged proteins and platelets to achieve anti-fouling and anti-Clotting. The results show that the anti-fouling capability of the poly(3,4-ethylenedioxythiophene) (PEDOT)/PSS coating is similar to that of the PEDOT/HEP coating. The anti-fouling capability of PEDOT/GO is higher than those of PEDOT/HEP and PEDOT/PSS. The reason for this is that GO exhibits negatively charged functional groups (COO−). The highest anti-fouling capability was found with the PEDOT/GO/HEP coating, indicating that electrochemical copolymerization of PEDOT with GO and HEP enhances the anti-fouling capability. Furthermore, the biocompatibility of the PEDOT coatings was tested with 3T3 cells for 1–5 days. The results show that all PEDOT composite coatings exhibited biocompatibility. The Blood Clotting Time (APTT) of PEDOT/GO/HEP was prolonged to 225 s, much longer than the 40 s of pristine SUS316L stainless steel (the control), thus greatly improving the anti-Blood-Clotting capability of cardiovascular stents.

  • hemocompatibility and anti fouling behavior of multilayer biopolymers immobilized on gold thiolized drug eluting cardiovascular stents
    Colloids and Surfaces B: Biointerfaces, 2019
    Co-Authors: Li Ying Huang, Ming-chien Yang, Hui-ming Tsou
    Abstract:

    Abstract To solve the thrombosis and restenosis problem in cardiovascular stent implantation for cardiovascular artery disease, chondroitin 6-sulfate (ChS) with heparin (HEP) have been used as drug carrier layers and alternatively covalently bonded on gold (Au)-dimercaptosuccinic acid (DMSA)-thiolized cardiovascular metallic (SUS316 L stainless steel, SS) stents. Sirolimus, a model drug, was encapsulated in the ChS-HEP alternative layers. The behavior of the drug in releasing and suppressing the growth of smooth-muscle cells (SMCs) was evaluated with 5-layer CHS-HEP coating on the SS stents. Moreover, hemocompatibility of Blood Clotting Time and platelet adhesion was performed. The results showed that the 5-layer ChS-HEP-modified SS stents displayed the greatest hemocompatibility, showing prolonged Blood Clotting Time of the activated partial thrombin Time (> 500 s) and less platelet adhesion to reduce thrombosis. Furthermore, sirolimus can be released continuously for more than 40 days with the 5-layer ChS-HEP coating and is beneficial for inhibiting the growth of SMCs; however, it does not affect the proliferation of endothelial cells, which can avoid restenosis formation. Therefore, the multilayers of ChS-HEP grafted onto the Au-DMSA-cardiovascular SS stents provide high potential for use as drug eluting stents.